Filing Details

Accession Number:
0001209191-14-071389
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-11-26 10:55:59
Reporting Period:
2014-11-25
Filing Date:
2014-11-26
Accepted Time:
2014-11-26 10:55:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1182129 Auxilium Pharmaceuticals Inc AUXL Pharmaceutical Preparations (2834) 233016883
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1547911 Varki Elizabeth Jobes C/O Auxilium Pharmaceuticals, Inc.
640 Lee Road
Chesterbrook PA 19087
Chief Compliance Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-11-25 20,000 $17.68 37,819 No 4 M Direct
Common Stock Acquisiton 2014-11-25 3,750 $18.30 41,569 No 4 M Direct
Common Stock Disposition 2014-11-25 4,052 $34.05 37,517 No 4 S Direct
Common Stock Disposition 2014-11-25 23,750 $34.03 13,767 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Nonqualified Stock Option (Right to Buy) Disposition 2014-11-25 20,000 $0.00 20,000 $17.68
Common Stock Nonqualified Stock Option (Right to Buy) Disposition 2014-11-25 3,750 $0.00 3,750 $18.30
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
20,000 2013-05-07 2022-05-07 No 4 M Direct
11,250 2014-02-07 2023-02-07 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.01 to $34.095, inclusive.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.015 to $34.095, inclusive.